WO1998010053A1 - Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures - Google Patents
Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures Download PDFInfo
- Publication number
- WO1998010053A1 WO1998010053A1 PCT/US1997/015252 US9715252W WO9810053A1 WO 1998010053 A1 WO1998010053 A1 WO 1998010053A1 US 9715252 W US9715252 W US 9715252W WO 9810053 A1 WO9810053 A1 WO 9810053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- composition
- dnase
- concentration
- ion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
Definitions
- the general field of this invention is the separation of hemopoietic cells.
- One aspect of this invention is a composition capable of removing or preventing cell clumps from forming in a cell separating device comprising: a) one or more DNase enzymes; b) one or more divalent cations; c) one or more chelating agents; and d) one or more buffers having a pKa between about 5 and about 9.
- a second aspect of this invention is the composition of the first embodiment with the addition of an RNase enzyme .
- a third aspect of this invention is a composition capable of removing or preventing cell clumps from forming in a cell separating device comprising: a) an RNase enzyme; b) one or more proteins; and c) one or more buffers with a pKa between about 5 and about 9.
- a fourth aspect of this invention is a kit for use in a cell separating device comprising the compositions of the first, second, or third aspect of this invention wherein said composition is provided in a separate closed container or disposable container further comprising one or more outlet ports, wherein at least one of said ports is optionally provided with a septum.
- a fifth aspect of this invention is a method of preventing cell clumping associated with an cell separation process comprising introducing the composition of the first, second, or third aspects of this invention into the initial cell population prior to cell separation in an amount sufficient to prevent cell clumping.
- a sixth aspect of this invention is a method of preventing cell clumping associated with cell separation process comprising introducing the composition of the first, second, or third aspects of the present invention into the cell population to be separated during the cell separation process in an amount sufficient to prevent cell clumping.
- a seventh aspect of this invention is a method of clearing a cell separation device of cell clumps following in the cell separation process comprising providing the composition of the first, second, or third aspects of the present invention,- and subsequently introducing into the device said composition under conditions which allow said cell clumps to clear.
- Figure 1 is a schematic diagram of a self- contained kit for use in cell separating procedures.
- Figure 2 compares the activity of DNase in Cell Separation Buffer and Cell Separation Cell Bag Supernatant, wherein both the Buffer and the Supernatant contain 2.5 mM MgCl 2 .
- the present invention utilizes several different nucleases, such as DNase and RNase, one or more divalent cations, and one or more chelating agents to prevent or break up clumps of cells during or after a cell separation procedure.
- DNase requires divalent metal ions for activity and relatively high levels of chelators are present in the solutions of the present invention. Therefore, down regulation of DNase activity would be expected.
- DNase activity is increased in the presence of excess chelator under these conditions.
- One aspect of this invention is a composition capable of removing or preventing cell clumps from forming in a cell separating device comprising: a) one or more DNase enzymes; b) one or more divalent cations; c) one or more chelating agents; and d) one or more buffers having a pKa between about 5 and about 9.
- Cell clumps form in cell separating devices during operation. They are problematic because they sequester cells from the efficient operation of a cell separating device which results in a decreased purity, yield, and viability of the final cell population.
- Cell separating devices use a variety of means to separate cells. Cells have been separated based on their size, density, shape, non-specific adsorption, or charge using very simple or complex devices (Edelman e_£_, al. , Methods of Enzymology 34:195-225 (1974), herein incorporated by reference) . Specific-binding methods, which immobilize a specific binding member on a solid phase, have also been used in simple and complex devices such as, for example, the ISOLEX ® series of cell sorters which utilize magnetic bead separation technology (Moubayad e___, al- , PCT Application No. WO 95124969, published September 21, 1995, and Moubayad et al ..
- any cell populations can be used, for example, T-cells, B-cells, dendritic cells, neutrophils, granulocytes, bacteria, or any other suspension of cells.
- non-nucleated cells such as platelts, for example, may be separated using the present invention.
- the cell population to be purified are mononuclear hematopoietic cells (MNC) , in particular the CD34+ cells.
- MNC can be derived from bone marrow, peripheral blood, or umbilical cord blood. Since obtaining bone marrow cells entails general anesthesia, it is preferable to obtain peripheral blood cells via leukapheresis , which is a non- invasive procedure performed without anesthesia.
- the patient or donor may undergo a treatment with cytokines and/or chemotherapeutic agents prior to cell collection, which agents mobilize CD34+ stem cells from the bone marrow into the peripheral blood.
- cytokines and/or chemotherapeutic agents prior to cell collection, which agents mobilize CD34+ stem cells from the bone marrow into the peripheral blood.
- it is not absolutely necessary to administer mobilizing agents to the donor.
- the preferred cell separating device is the ISOLEX ® cell separating series, such as the ISOLEX ® 50, ISOLEX ® 300 (also referred to as the ISOLEX ® 300SA) , and ISOLEX ® 300i (Baxter Healthcare Corp., Irvine, California).
- the ISOLEX ® 300i was used to perform the experiments reported below.
- This cell separator uses prepackaged buffers to suspend cell populations to be separated. A spinning membrane washes and concentrates cells. Magnetic beads coupled with antibodies specific for cell populations bind to the desired cell populations. A primary magnet is used to immobilize the magnetic beads and associated cells. Cells are then released using a releasing agent which competitively binds to the specific antibody (Tseng-Law fi al-, PCT Application No. WO 95/34817, published
- the ISOLEX ® series of cell separators is described in the following materials, which are herein incorporated by reference: The ISOLEX ® 300i Operators Manual (document 120-9123) ; ISOLEX ® 300i Brochure (document IT 300i 3/96); ISOLEX ® 300 Brochure (documents ITPR34 2/96 and BT/IT-3877.02.01- 2/96) ; and ISOLEX ® 50 Brochure (document BT/IT-
- DNase enzymes are a family of enzymes capable of degrading DNA. DNases are known to come in several different forms, such as DNase I, DNase II, Endo-DNase (Ando et al .. European Patent No. 0 060 465 Bl (June 16, 1987) and Ando et al . , U.S. Patent No. 4,430,432, issued February 7, 1984, herein incorporated by reference)); DNase B, (Adams fit al. , PCT Application No.
- WO 96/06174 (February 29, 1996), herein incorporated by reference); DNase , ⁇ , and y (Tanu a, PCT Application No. WO 96/07735 (March 14, 1996), herein incorporated by reference) .
- Any of these DNases, either alone or in combination, or any other form of DNase, are operable in the present invention.
- DNase I and other divalent cation-dependent DNases, especially DNase I are contemplated.
- Divalent cations are known to modulate DNase I activity (Campbell fit al- , J. Biol . Chem. 255(8) :3726- 3735 (1980) , herein incorporated by reference) .
- magnesium and calcium ions are used to obtain high levels of DNase I activity, although other divalent cations such as zinc, manganese, and cobalt may also be used.
- DNase II activity does not require these divalent cations .
- Chelating agents which bind divalent cations are well-known in the art. Any chelating agent which may bind divalent cations may be used in the present invention. Preferred chelating agents are those that would be acceptable for use with a cell sample that was to be reintroduced into the patient.
- the present invention uses the bidentate chelators citrate ion and EDTA, although complex chelators such as heparin are also acceptable.
- citrate ions completely inhibit magnesium-activated but not manganese- activated DNase I activity (Worthington Catalog Price List, Worthington Chemical Co., p. 67 (1996-1997)), herein incorporated by reference) . Therefore, it is unexpected that DNase I activity would be maintained when significant concentrations of citrate ion are present in the initial cell separation mixture as in the present invention.
- the buffer would have a pKa between about 5 and about 9, more preferably between about 6 and about 8. Specific buffers are numerous, and are reviewed in
- Specific buffers include, for example, phosphate buffered saline, tris buffered saline, HEPES, citrate/phosphate, phosphate, tris, boric acid, MOPS, TES, PIPS, acetate, succinate, maleate, barbatol, glycine/HCl, carbonate/bicarbonate, HEPPS, MES, bis-tris, and MEM.
- proteins are contemplated.
- Preferred proteins are albumin and other serum proteins such as immunoglobulins .
- Immunoglobulins may be provided as Gammagard ® (Baxter Hyland, Glendale, California) .
- Other useful reagents include gelatin or polyethylene glycol (PEG) .
- PEG polyethylene glycol
- different albumins may be more preferable.
- human serum albumin is preferable over albumin from other species .
- the following ranges of concentration of the reagents are particularly useful : DNase between about 0.1 and about 100 KU/ml, citrate ion provided as a salt at a concentration between about 1 and about 100 mM, magnesium ion provided as a salt at a concentration between about 0.1 and about 100 mM, albumin provided at a concentration between about 0.1 and about 10%, all in a buffer with a pKa between 6 and 8.
- the DNase is provided at about 10
- the citrate ion at about 14 mM the citrate ion at about 14 mM
- the magnesium ion at about 2.5 mM the albumin at about 1%
- the albumin at about 1%, in phosphate buffered saline.
- RNase may be added to this composition.
- the addition of RNase to the composition containing DNase allows the degradation of DNA and RNA which further enhances the ability of both the components to prevent or dissolve cell clumps that form during operation of cell separating devices. This composition will therefore further enhance the ability of the present invention to reduce such cell clumping because cell clumps are held together by both DNA and RNA.
- RNase is useful at a concentration range of 0.1 to about 1000 KU/ml. Preferably about 100 to about 400 KU/ml .
- RNase is a family of enzymes which degrades RNA and is available from a wide variety of biological sources and commercial suppliers. For example, RNase A, RNase B, RNase C, and RNase H are available from Sigma Chemical Co. (St. Louis, MO). RNases are generally inhibited by heavy metals, and are not dependent on the presence of divalent metal cations for its activity. The definitions of albumin and buffers suitable for use with RNase is as discussed above for the various DNase enzymes .
- compositions capable of removing or preventing cell clumps from forming in a cell separating device comprising: a) one or more RNase enzymes; b) one or more proteins; and c) one or more buffers with a pKa between about 5 and about 9.
- An amount of the composition sufficient to prevent cell clumping results in the increased efficiency in the operation of cell separation procedures, such as an increase in any one of cell purity, viability, or yield.
- kits for use in a cell separating device comprising the compositions of the first, second, or third aspects of this invention wherein said composition is provided in a disposable container further comprising one or more outlet ports, at least one of said ports provided with a septum.
- a disposable container further comprising one or more outlet ports, at least one of said ports provided with a septum.
- the solutions may be provided in collapsible plastic containers, such as those used to store blood.
- Such containers are routinely made from biocompatable polymers, for example, polyvinyl chloride (PVC) , polycarbonate, and polypropylene, all of which are readily commercially available.
- PVC polyvinyl chloride
- polycarbonate polycarbonate
- polypropylene all of which are readily commercially available.
- cell separation devices such as the ISOLEX ® 50, 300 (also referred to as ISOLEX ® 300SA) , and 300i series, come in a wide variety of mechanisms, shapes, and port size, number, and orientation, the particular components of the kit are linked to the particular cell separating device. Therefore, a wide range of disposable formats are envisioned and necessary.
- detachable inlet and outlet ports which carry fluids during operation of the cell separating device would be provided for use with the disposable container in order to minimize the possibility of contamination during operation of the cell separating device.
- these ports would contain a septum, such as a physical barrier through which a syringe needle may be inserted to inject various reagents.
- a membrane filter capable of removing etiological agents such as bacteria, viruses, and parasites from solution, would preferably be included with at least one of the ports.
- the components of the present invention may be provided pre-mixed with reagents, or may be provided separately, preferably in a more concentrated form in a separate closed container, for example, a vial.
- a vial Preferably, such a vial would contain DNase and/or RNase with or without divalent cations.
- a septum may also be provided to the device and/or container to remove etiological agents such as bacteria, viruses, and parasites from air as it is taken into the cell separating device.
- the kit comprises all reagents and disposable hardware, such as reagent containers, tubing, filters, membranes, chambers, manifolds, and other ancillary elements necessary to perform a cell separation process using a particular cell separating device (such as primary and secondary chambers, and spinning membranes, for the ISOLEX ® 300i Cell Separating System) , in a completely self-contained, sterile system.
- reagent containers such as reagent containers, tubing, filters, membranes, chambers, manifolds, and other ancillary elements necessary to perform a cell separation process using a particular cell separating device (such as primary and secondary chambers, and spinning membranes, for the ISOLEX ® 300i Cell Separating System)
- a particular cell separating device such as primary and secondary chambers, and spinning membranes, for the ISOLEX ® 300i Cell Separating System
- Figure 1 Arrows indicate preferred sites of introducing the compositions of this invention. However, these compositions may be introduced at any site where the solution is to, at some time, pass through locations in the kit where cell clumps form.
- Another aspect of this invention is a method of preventing cell clumping associated with a cell separation process comprising: a) providing the composition of the first, second, or third aspects of this invention into the mixture to be separated in an amount sufficient to prevent cell clumping during the cell separation process.
- An amount of the composition sufficient to prevent cell clumping results in the increased efficiency of the operation of cell separation procedures, such as an increase in any one of the parameters of cell purity, viability, or yield.
- Another aspect of this invention is a method of preventing cell clumping associated with a cell separation process comprising: providing the composition of the first, second, or third aspects of the present invention during the cell separation process rather than prior to cell separation, in an amount sufficient to prevent cell clumping. This procedure reduces the amount of clumps which are formed and results in an increase in the yield of the final cell population obtained. Increased purity and viability of resulting cell population are also envisioned.
- the compositions may be added at any point or time before or during the cell separation procedure, preferably prior to the first biochemical or immunological reaction.
- Another aspect of this invention is a method of clearing a cell separation device of cell clumps following a cell separation procedure comprising: a) providing the composition of the first, second, or third embodiment of the present invention; and b) subsequently washing the device with said composition under conditions which allow said cell clumps to clear.
- cell separation devices become clogged from clumps formed during operation.
- cell separating devices comprise extensive lengths of small tubing and convoluted passages between plates which are kept very close together. The ability to clean this tubing and these passages is desirable to maintain efficient operation of the cell separating device. Therefore, the compositions discussed in the previous embodiments may also be used to clear out existing clumps which interfere with the operation of such cell separating devices.
- Cell Separation Buffer Standard buffer provided in the ISOLEX ® 300i cell separating device (Cell Separation Buffer) was used to determine DNase activity.
- Cell separation buffer is comprised of phosphate buffered saline (PBS), 14.6 mM citrate, and 1% human serum albumin. This buffer was made 0 to 12.5 ⁇ g in DNase (Pulmozyme ® , Genentech, Inc, South San Francisco, California) and 2.5mM of MgCl 2 .
- DNase activity was measured using the DNA-methyl green substrate assay of Sinicropi fit al- , Analytical Biochemistry. 222:351-358 (1994), herein incorporated by reference (see generally Garland et al .. U.S. Patent No.
- Cell Separation Cell Bag Supernatant DNase activity in Cell Separation Buffer with the addition and subsequent removal of cell populations (hereinafter "Cell Separation Cell Bag Supernatant") prior to the addition of DNA-methyl green complex (referred to herein as Cell Separation Cell Bag Supernatant) was also determined.
- Cell Separation Cell Bag Supernatant was made by adding greater than 10 10 peripheral blood mononuclear cells (PBMNC) into Cell Separation Buffer and removing the cells by centrifugation .
- PBMNC peripheral blood mononuclear cells
- Example 1 Using the general procedure discussed above in Example I, the effects of varying the concentration of divalent cations was investigated. Specifically, magnesium ion concentration, in the absence of calcium ion, was investigated. The results are displayed in Table 1-a. The linear range used to calculate the relative activity was 1 to 7.5 ⁇ g of DNase.
- Standard refers to a buffer containing 4 mM MgCl 2 and 4 mM CaCl 2 which has been determined to optimized DNase I activity (Sinicropi et al . (1994)) and "NA" means non-applicable.
- D-PBS Dulbecco's PBS
- D-PBS Dulbecco's PBS
- the composition of which is set forth in the Gibco BRL Product Catalog and Reference Guide (1995-1996) (herein incorporated by reference) as; 0.2 g/L of KCL, 0.2 g/L KH 2 P0 4 , 8.0 g/L of NaCl, 1.15 g/L of Na 2 HP0 relaxation, and 2.16 g/L of Na 2 HP0 4 7H 2 0.
- a small portion of a primary chamber clump from an ISOLEX ® Cell Separator (previously stored for 2 weeks at 4°C) was incubated with 471 KU of DNase I (containing chymotrypsin activity) (Sigma Chemical Co., St. Louis, MO) in D-PBS without Mg++, Ca++, or citrate.
- DNase I containing chymotrypsin activity
- D-PBS without Mg++, Ca++, or citrate.
- a fresh clump from an ISOLEX ® 300i cell separation procedure of greater than 10 10 PBMNC's was further tested.
- the wet weight of the clump was measured as 1.841 g, then the clump was divided into eight equal portions for the following treatments: PBS control, mechanical trituration, a DNase I (with chymotrypsin; all previous examples used Pulmozyme ® DNase I which does not contain chymotrypsin) (Sigma Chemical Co., St. Louis, MO) treatment in PBS, chymopapain (Baxter Healthcare, Irvine, California), plasmin (Sigma Chemical, St. Louis, MO), DNase I (with chymotrypsin) /plasmin mixture.
- PBS control mechanical trituration
- a DNase I with chymotrypsin; all previous examples used Pulmozyme ® DNase I which does not contain chymotrypsin
- Pulmozyme ® DNase I which does not contain chymotrypsin
- PFC physiological fibrin clot
- the PFC was generated by adding 5 units of thrombin (Ila) (Baxter Hyland, Glendale, California) to a 3 mg/ml solution of topical fibrinogen complex (TFC) (Baxter Hyland, Glendale, California) .
- Y Cell number and viability were determined after 1 hr (Clump #1 ) or 15 minutes (Clump #2). ⁇ Viability was determined by microscopy or calcien (Clump # 1 ) or by acridine orange/propidium iodide (Clump #2).
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002264885A CA2264885A1 (en) | 1996-09-04 | 1997-08-29 | Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures |
EP19970940686 EP0938543A4 (en) | 1996-09-04 | 1997-08-29 | Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures |
AU42407/97A AU733602B2 (en) | 1996-09-04 | 1997-08-29 | Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70740596A | 1996-09-04 | 1996-09-04 | |
US08/707,405 | 1996-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998010053A1 true WO1998010053A1 (en) | 1998-03-12 |
Family
ID=24841563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/015252 WO1998010053A1 (en) | 1996-09-04 | 1997-08-29 | Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0938543A4 (en) |
AU (1) | AU733602B2 (en) |
CA (1) | CA2264885A1 (en) |
WO (1) | WO1998010053A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068254A1 (en) * | 2002-02-18 | 2003-08-21 | University Of Southampton | Glycosaminoglycan-dnase combination therapy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004681A (en) * | 1987-11-12 | 1991-04-02 | Biocyte Corporation | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5635387A (en) * | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3009224B2 (en) * | 1994-03-04 | 2000-02-14 | ジェネンテック インコーポレイテッド | Improved DNase liquid solution |
-
1997
- 1997-08-29 CA CA002264885A patent/CA2264885A1/en not_active Abandoned
- 1997-08-29 EP EP19970940686 patent/EP0938543A4/en not_active Withdrawn
- 1997-08-29 WO PCT/US1997/015252 patent/WO1998010053A1/en not_active Application Discontinuation
- 1997-08-29 AU AU42407/97A patent/AU733602B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004681A (en) * | 1987-11-12 | 1991-04-02 | Biocyte Corporation | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5635387A (en) * | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
Non-Patent Citations (1)
Title |
---|
See also references of EP0938543A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068254A1 (en) * | 2002-02-18 | 2003-08-21 | University Of Southampton | Glycosaminoglycan-dnase combination therapy |
Also Published As
Publication number | Publication date |
---|---|
EP0938543A1 (en) | 1999-09-01 |
AU733602B2 (en) | 2001-05-17 |
CA2264885A1 (en) | 1998-03-12 |
EP0938543A4 (en) | 2002-10-29 |
AU4240797A (en) | 1998-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0395355B1 (en) | Release of cells from affinity matrices | |
AU2021202347B2 (en) | Cell separation devices, systems, and methods | |
EP0438520B1 (en) | System for magnetic affinity cell separation from cell concentrates | |
US7316932B2 (en) | Method for separating cells | |
EP0653062B1 (en) | Continuous centrifugation process for the separation of biologic components from heterogeneous cell populations | |
Halliday et al. | Delayed hypersensitivity to chemically induced tumors in mice and correlation with an in vitro test | |
AU768538B2 (en) | Method for enriching or depleting tumour cells obtained from a body fluid and kit suitable for this purpose | |
EP0973873A1 (en) | Method of harvesting rare cells from blood products | |
WO2002101029A1 (en) | Method of separating and concentrating cells for kidney regfneration | |
Sowemimo‐Coker et al. | White cell subsets in apheresis and filtered platelet concentrates | |
AU733602B2 (en) | Compositions containing nucleases and chelators to enhance the recovery of cells during cell separating procedures | |
Johnsen et al. | Selective loss of progenitor subsets following clinical CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation | |
CA2893828A1 (en) | Point of care isolation and concentration of blood cells | |
Auditore-Hargreaves et al. | Selection and transplantation of hematopoietic stem and progenitor cells | |
Bjöorkstrand et al. | Retroviral-Mediated Gene Transfer of CD34-Enriched Bone Marrow and Peripheral Blood Cells During Autologous Stem Cell Transplantation for Multiple Myeloma. Huddinge Hospital and Karolinska Institute, Huddinge, Sweden | |
WO2012061291A2 (en) | Methods and compositions for cell separation of blood tissues | |
CA2096194A1 (en) | Transport medium for microorganism specimen containing white blood cell lytic agents | |
US20240026288A1 (en) | Method and device for target cell separation | |
AU7798294A (en) | Method for obtaining a cell population enriched in stem cells and compositions derived therefrom | |
CA2405881C (en) | Method for separating cells | |
Glimm et al. | Evidence of similar effects of short-term culture on the initial repopulating activity of mobilized peripheral blood transplants assessed in NOD/SCID-β2microglobulinnull mice and in autografted patients | |
Alföldy et al. | In situ effector pathways of allograft destruction: 3. Plasminogen activator activity in rat renal allografts | |
JPH11266852A (en) | Cell separator | |
Kenyon et al. | High-density particles: a novel, highly efficient cell separation technology | |
Mrowiec et al. | Apyrase, ascorbic acid and aprotinin ameliorate the storage lesion in pelleted platelet preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2264885 Country of ref document: CA Ref country code: CA Ref document number: 2264885 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997940686 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998512760 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997940686 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997940686 Country of ref document: EP |